End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33651099/
GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This retrospective analysis of GOYA aimed to assess t ...
-
Mark FeslerApril 08, 2021While one would assume a link between end of treatment pet cR vs other response category would predict pfs in an aggressive and curable disease , it’s always nice to have a study proving this...